Geoffrey Hodge

Cellular Origins has appointed Geoffrey Hodge to its board

Cellular Origins has announced the appointment of Geoffrey Hodge to its board as Non-Executive Director.

Leveraging extensive expertise, knowledge and experience in cell therapy and biomanufacturing, Geoff’s appointment will strengthen the company’s strategic vision and technical capability to deliver accelerated growth and continued commercial success.

Geoffrey was most recently CEO of SOTIO Biotech US and CTO of Unum Therapeutics, both autologous cell therapy companies.

Prior to entering the cell therapy sector, Geoff co-founded Xcellerex, where he was the primary inventor of the XDR single-use bioreactor and head of the CDMO biomanufacturing services business, which helped the company grow to $50m in revenue prior to its acquisition by GE Healthcare.

In addition to his role on the Board of Cellular Origins, Geoffrey will remain part of the company’s Scientific Advisory Board, where his extensive experience in developing biomanufacturing technology and proven commercial success has already helped to shape the company’s strategic direction.

He will work closely alongside the board and leadership team to accelerate growth and ensure continued development of the company’s robotic platform for cost- and space-efficient manufacture of cell therapies, Constellation.

Dr Edwin Stone, CEO at Cellular Origins, said: “Geoff has unique experience having built businesses that have transformed bioprocess manufacturing. There are very few individuals who have been through this journey.”

Geoffrey added: “Cellular Origins offers a transformative, industry-ready solution that addresses the challenges of manufacturing cell therapies at scale. I look forward to joining the Board and further deepening my involvement in the company at this exciting time in its development and growth.”